Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. More Details
Excellent balance sheet with weak fundamentals.
Share Price & News
How has Replimune Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: REPL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: REPL's weekly volatility has decreased from 14% to 9% over the past year.
7 Day Return
1 Year Return
Return vs Industry: REPL exceeded the US Biotechs industry which returned 33.3% over the past year.
Return vs Market: REPL exceeded the US Market which returned 22% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Replimune Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StDo Institutions Own Replimune Group, Inc. (NASDAQ:REPL) Shares?
6 months ago | Simply Wall StIs Replimune Group, Inc. (NASDAQ:REPL) Popular Amongst Insiders?
1 year ago | Simply Wall StReplimune Group (NASDAQ:REPL) Is In A Good Position To Deliver On Growth Plans
Is Replimune Group undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate REPL's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate REPL's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: REPL is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: REPL is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate REPL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: REPL is overvalued based on its PB Ratio (7x) compared to the US Biotechs industry average (4.2x).
How is Replimune Group forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: REPL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: REPL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: REPL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if REPL's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if REPL's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: REPL is forecast to be unprofitable in 3 years.
How has Replimune Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: REPL is currently unprofitable.
Growing Profit Margin: REPL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: REPL is unprofitable, and losses have increased over the past 5 years at a rate of 46.2% per year.
Accelerating Growth: Unable to compare REPL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: REPL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).
Return on Equity
High ROE: REPL has a negative Return on Equity (-26.61%), as it is currently unprofitable.
How is Replimune Group's financial position?
Financial Position Analysis
Short Term Liabilities: REPL's short term assets ($252.4M) exceed its short term liabilities ($13.0M).
Long Term Liabilities: REPL's short term assets ($252.4M) exceed its long term liabilities ($39.9M).
Debt to Equity History and Analysis
Debt Level: REPL's debt to equity ratio (3.8%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if REPL's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: REPL has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: REPL has sufficient cash runway for 3 years if free cash flow continues to reduce at historical rates of 56.4% each year.
What is Replimune Group current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate REPL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate REPL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if REPL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if REPL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of REPL's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Philip Astley-Sparke (49 yo)
Mr. Philip Astley-Sparke, FSA, has been the Chairman of uniQure N.V. since September 22, 2016 and its Director since June 15, 2015. He is a Co-founder of Replimune Group, Inc. and served as its Executive C...
CEO Compensation Analysis
Compensation vs Market: Philip's total compensation ($USD2.16M) is below average for companies of similar size in the US market ($USD3.85M).
Compensation vs Earnings: Philip's compensation has increased whilst the company is unprofitable.
|CEO & Director||1yr||US$2.16m||2.84% |
|Principal Accounting Officer||1.08yrs||US$2.10m||no data|
|Chief Business Officer||5.17yrs||US$1.23m||0.38% |
|Chief Operating Officer||5.25yrs||US$1.30m||2.12% |
|Chief Medical Officer||0.50yr||no data||0.0022% |
Experienced Management: REPL's management team is considered experienced (3.1 years average tenure).
|CEO & Director||1yr||US$2.16m||2.84% |
|Independent Director||3.25yrs||US$199.00k||0.015% |
|Independent Director||5.33yrs||US$174.50k||0% |
|Independent Director||6yrs||US$161.50k||0% |
|Independent Director||5.67yrs||US$126.50k||0% |
|Independent Non-Executive Director||2.67yrs||US$165.50k||0% |
|Independent Director||0.75yr||no data||no data|
|Director||1yr||no data||no data|
|Independent Director||3.5yrs||US$179.00k||0% |
|Independent Chairman of the Board||0.75yr||US$169.00k||0% |
Experienced Board: REPL's board of directors are considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 29.8%.
Replimune Group, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Replimune Group, Inc.
- Ticker: REPL
- Exchange: NasdaqGS
- Founded: 2015
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.095b
- Shares outstanding: 45.96m
- Website: https://replimune.com
Number of Employees
- Replimune Group, Inc.
- 500 Unicorn Park
- 3rd Floor
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|REPL||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Jul 2018|
|7R8||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jul 2018|
Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intend...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/14 23:18|
|End of Day Share Price||2021/01/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.